| Literature DB >> 29950467 |
Toshinaga Tsuji1, Ko Matsudaira2, Hiroki Sato1, Jeffrey Vietri3, Dena H Jaffe4.
Abstract
OBJECTIVES: This study investigated the relationship between presenteeism and health-related quality of life (HRQoL) among Japanese adults with chronic lower back pain (CLBP).Entities:
Keywords: chronic lower back pain; health-related quality of life; presenteeism
Mesh:
Year: 2018 PMID: 29950467 PMCID: PMC6042623 DOI: 10.1136/bmjopen-2017-021160
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow of study participants. NHWS, National Health and Wellness Survey.
Sociodemographic and general health characteristics among employed patients with CLBP by level of presenteeism
| Total | No presenteeism | Low presenteeism | High presenteeism (≥30%) (n=114) | P values* | |
| Age (years) | |||||
| Mean±SD | 50.9±13.0 | 50.2±13.8 | 52.7±12.7 | 50.1±12.8 | 0.397 |
| Age groups | 0.819 | ||||
| <40 years (%) | 49 (20.5) | 11 (20.4) | 12 (16.9) | 26 (22.8) | |
| 40–49 years (%) | 57 (23.8) | 13 (24.1) | 14 (19.7) | 30 (26.3) | |
| 50–59 years (%) | 65 (27.2) | 15 (27.8) | 21 (29.6) | 29 (25.4) | |
| ≥60 years (%) | 68 (28.5) | 15 (27.8) | 24 (33.8) | 29 (25.4) | |
| Female (%) | 84 (35.1) | 10 (18.5) | 24 (33.8) | 50 (43.9)† | 0.006 |
| Married/living with partner (%) | 157 (65.7) | 37 (68.5) | 50 (70.4) | 70 (61.4) | 0.401 |
| Annual household income | 0.801 | ||||
| <¥3 million (%) | 29 (12.1) | 7 (13.0) | 6 (8.5) | 16 (14.0) | |
| ¥3 million to <¥5 million (%) | 53 (22.2) | 10 (18.5) | 16 (22.5) | 27 (23.7) | |
| ¥5 million to <¥8 million (%) | 72 (30.1) | 19 (35.2) | 18 (25.4) | 35 (30.7) | |
| ¥8 million or more (%) | 70 (29.3) | 15 (27.8) | 26 (36.6) | 29 (25.4) | |
| Decline to answer (%) | 15 (6.3) | 3 (5.6) | 5 (7.0) | 7 (6.1) | |
| Education level (completed university education vs not) (%) | 134 (56.1) | 35 (64.8) | 37 (52.1) | 62 (54.4) | 0.323 |
| Charlson Comorbidity Index (CCI) | |||||
| Mean±SD | 0.41±2.16 | 0.69±4.35 | 0.23±0.57 | 0.39±0.80 | 0.495 |
| Body mass index category‡ | 0.433 | ||||
| Underweight (%) | 22 (9.3) | 3 (5.6) | 4 (5.7) | 15 (13.3) | |
| Normal weight (%) | 156 (65.8) | 38 (70.4) | 51 (72.9) | 67 (59.3) | |
| Overweight (%) | 49 (20.7) | 10 (18.5) | 13 (18.6) | 26 (23.0) | |
| Obese (%) | 10 (4.2) | 3 (5.6) | 2 (2.9) | 5 (4.4) | |
| Smoking behaviour | 0.465 | ||||
| Never smoked (%) | 82 (34.3) | 21 (38.9) | 25 (35.2) | 36 (31.6) | |
| Former smoker (%) | 75 (31.4) | 20 (37.0) | 21 (29.6) | 34 (29.8) | |
| Current smoker (%) | 82 (34.3) | 13 (24.1) | 25 (35.2) | 44 (38.6) | |
| Drink alcohol (%) | 193 (80.8) | 43 (79.6) | 61 (85.9) | 89 (78.1) | 0.409 |
| Vigorous exercise at least 1 day in the past month (%) | 109 (45.6) | 24 (44.4) | 38 (53.5) | 47 (41.2) | 0.259 |
*Continuous variables (eg, age and CCI) were compared using a one-way analysis of variance test (p values presented) and the Kruskal-Walllis non-parametric tests. Results from parametric and non-parametric tests were similar. Categorigal variables were compared using χ 2 or Fisher’s exact test.
†Post hoc pairwise comparisons versus no presenteeism were conducted using the Bonferroni correction. For variables with more than two categories, values in the same row were tested for equality of column proportions. Values with a subscript were significantly different from those with no presenteeism at p<0.05.
‡Data were not provided for n=2 respondents (n=1 low preseenteeism; n=1 high presenteeism).
CLBP, chronic lower back pain.
Pain characteristics of employed patients with CLBP according to levels of presenteeism
| Total | No presenteeism | Low presenteeism | High presenteeism (≥30%) (n=114) | P values* | |
| Severity of pain in prior week (0–10) | |||||
| Mean±SD | 4.3±2.2 | 3.6±2.1 | 3.8±2.2 | 4.9±2.2† | <0.001 |
| Severity of pain currently (0–10) | |||||
| Mean±SD | 4.5±2.3 | 3.9±2.5 | 4.0±2.3 | 5.1±2.1† | 0.001 |
| Duration of lower back pain | |||||
| Mean±SD | 112.7±120.5 | 112.6±130.3 | 115.2±124.6 | 111.2±113.9 | 0.977 |
| Additional pains (total#, 0–6) | |||||
| Mean±SD | 1.6±1.6 | 1.1±1.4 | 1.4±1.5 | 1.9±1.6† | 0.003 |
| Severity of lower back pain‡ | 0.004 | ||||
| Mild (%) | 114 (51.8) | 33 (66.0) | 40 (61.5) | 41 (39.0) | |
| Moderate (%) | 88 (40.0) | 16 (32.0) | 21 (32.3) | 51 (48.6) | |
| Severe (%) | 18 (8.2) | 1 (2.0) | 4 (6.2) | 13 (12.4) | |
| Frequency of problems with pain | 0.259 | ||||
| Daily (%) | 96 (40.2) | 19 (35.2) | 26 (36.6) | 51 (44.7) | |
| 4–6 times a week (%) | 38 (15.9) | 3 (5.6) | 17 (23.9) | 18 (15.8) | |
| 2–3 times a week (%) | 52 (21.8) | 16 (29.6) | 14 (19.7) | 22 (19.3) | |
| Once a week (%) | 19 (7.9) | 6 (11.1) | 5 (7.0) | 8 (7.0) | |
| 2–3 times a month (%) | 21 (8.8) | 6 (11.1) | 5 (7.0) | 10 (8.8) | |
| Once a month or less often (%) | 13 (5.4) | 4 (7.4) | 4 (5.6) | 5 (4.4) | |
| Type of diagnosing doctor for lower back pain | 0.765 | ||||
| Orthopaedist (%) | 199 (83.3) | 44 (81.5) | 61 (85.9) | 94 (82.5) | |
| Other (%) | 40 (16.7) | 10 (18.5) | 10 (14.1) | 20 (17.5) | |
| Type of prescribing doctor | 0.124 | ||||
| Orthopaedist (%) | 56 (70.9) | 11 (73.3) | 16 (88.9) | 29 (63.0) | |
| Other (%) | 23 (29.1) | 4 (26.7) | 2 (11.1) | 17 (37.0) | |
| Current use of a prescription medication for pain | 0.028 | ||||
| NSAID (%) | 58 (24.3) | 10 (18.5) | 17 (23.9) | 31 (27.2) | |
| Other (%) | 15 (13.2) | 5 (9.3) | 1 (1.4) | 15 (13.2) | |
| None (%) | 160 (66.9) | 39 (72.2) | 53 (74.6) | 68 (59.6) | |
| Use of an OTC or herbal product for pain (%) | 81 (33.9) | 16 (29.6) | 23 (32.4) | 42 (36.8) | 0.621 |
| Depression severity | |||||
| Mean±SD | 5.5±5.6 | 3.6±3.6 | 3.9±4.0 | 7.5±6.5† | <0.001 |
*Continuous variables (eg, severity of pain) were compared using one-way analysis of variance or Kruskal-Walllis non-parametric tests (p values presented). Results from parametric and non-parametric tests were similar. Categorigal variables were compared using χ 2 or Fisher’s exact test.
†Post hoc pairwise comparisons versus no presenteeism were conducted using the Bonferroni correction. For variables with more than two categories, values in the same row were tested for equality of column proportions. Values with a subscript were significantly different from those with no presenteeism at p<0.05.
‡Data were missing for n=19 respondents.
CLBP, chronic lower back pain; NSAID, non-steroidal anti-inflammatory drug; OTC, over-the-counter; PHQ-9, Patient Health Questionnaire.
HRQoL (SF-36 summary) outcomes of CLBP respondents according to level of presenteeism
| Total | No presenteeism | Low presenteeism | High presenteeism (≥30%) (n=114) | P values* | |
| Mean±SD | Mean±SD | Mean±SD | Mean±SD | ||
| HRQoL: summary scores (US norms) | |||||
| Mental component summary | 45.0±10.3 | 50.8±6.3 | 48.2±9.3 | 40.2±10.3† | <0.001 |
| Physical component summary | 48.2±6.6 | 51.0±5.7 | 49.9±5.7 | 45.7±6.7† | <0.001 |
| SF-6D health utility index | 0.68±0.11 | 0.75±0.09 | 0.72±0.10 | 0.63±0.09† | <0.001 |
| HRQoL: health profile scores (Japanese norms) | |||||
| Physical functioning | 46.5±13.0 | 49.3±12.3 | 49.8±9.9 | 43.1±14.2† | 0.001 |
| Physical role limitations | 44.8±12.6 | 51.8±8.7 | 48.7±9.3 | 39.0±13.5† | <0.001 |
| Bodily pain | 40.7±8.2 | 44.5±8.2 | 42.9±7.1 | 37.4±7.6† | <0.001 |
| General health | 43.1±10.3 | 49.6±9.1 | 45.6±9.0† | 38.5±9.5† | <0.001 |
| Vitality | 42.5±10.2 | 48.3±6.5 | 45.8±9.8 | 37.8±9.7† | <0.001 |
| Social functioning | 44.6±12.3 | 50.5±8.3 | 48.5±11.0 | 39.5±12.7† | <0.001 |
| Emotional role limitations | 46.6±12.1 | 52.8±7.9 | 50.6±8.3 | 41.2±13.3† | <0.001 |
| Mental health | 44.3±10.6 | 49.6±8.3 | 46.9±10.5 | 40.3±10.0† | <0.001 |
*Variables were compared using a one-way analysis of variance test.
†Post hoc pairwise comparisons versus no presenteeism were conducted using the Bonferroni correction and were significantly different from those with no presenteeism at p<0.05.
CLBP, chronic lower back pain; HRQoL; health-related quality of life; SF-6D, Short Form-6 dimension; SF-36, Short Form-36.
HRQoL (SF-36 summary) outcomes of CLBP respondents according to level of presenteeism, adjusted for covariates*
| No presenteeism (0%) (n=54) | Low presenteeism | High presenteeism | Low versus none (ref) | High versus none (ref) | |||||||
| Mean | SE | 95% CI | Mean | SE | 95% CI | Mean | SE | 95% CI | P values | P values | |
| HRQoL: summary scores (US norms) | |||||||||||
| Mental component summary | 50.3 | 1.5 | 47.3 to 53.4 | 47.8 | 1.4 | 45.2 to 50.5 | 40.4 | 1.1 | 38.2 to 42.6 | 0.128 | |
| Physical component summary | 47.8 | 1.0 | 45.9 to 49.8 | 47.4 | 0.9 | 45.7 to 49.1 | 43.6 | 0.7 | 42.21 to 45.0 | 0.664 | |
| SF-6D health utility index | 0.72 | 0.02 | 0.69 to 0.75 | 0.70 | 0.01 | 0.68 to 0.73 | 0.61 | 0.01 | 0.59 to 0.63 | 0.298 | |
| HRQoL: health profile scores (Japanese norms) | |||||||||||
| Physical functioning | 41.5 | 2.0 | 37.6 to 45.4 | 44.0 | 1.7 | 40.6 to 47.4 | 38.2 | 1.4 | 35.5 to 41.0 | 0.244 | 0.094 |
| Physical role limitations | 48.4 | 1.8 | 44.8 to 52.0 | 46.5 | 1.6 | 43.3 to 49.7 | 36.7 | 1.3 | 34.0 to 39.3 | 0.338 | |
| Bodily pain | 42.8 | 1.3 | 40.3 to 45.3 | 41.5 | 1.1 | 39.3 to 43.7 | 36.7 | 0.9 | 34.9 to 38.5 | 0.334 | |
| General health | 46.9 | 1.5 | 43.9 to 49.8 | 43.0 | 1.3 | 40.3 to 45.6 | 36.6 | 1.1 | 34.5 to 38.7 | ||
| Vitality | 46.0 | 1.5 | 43.2 to 48.9 | 43.5 | 1.3 | 41.0 to 46.0 | 37.0 | 1.1 | 35.0 to 39.1 | 0.099 | |
| Social functioning | 49.0 | 1.9 | 45.2 to 52.8 | 47.6 | 1.7 | 44.2 to 50.9 | 38.4 | 1.4 | 35.6 to 41.1 | 0.479 | |
| Emotional role limitations | 51.5 | 1.8 | 47.9 to 55.1 | 50.4 | 1.6 | 47.3 to 53.6 | 41.0 | 1.3 | 38.4 to 43.6 | 0.579 | |
| Mental health | 48.2 | 1.6 | 45.0 to 51.4 | 45.5 | 1.4 | 42.7 to 48.3 | 39.7 | 1.2 | 37.4 to 42.0 | 0.120 | |
*Models were adjusted for age, sex, Charlson Comorbidity Index scores, body mass index, marital status, education, household income, cigarette smoking, alcohol use and exercise. Adjusted mean values were calculated for each subgroup of according to presenteeism with comparisons versus no presenteeism as the reference group. Bolded values represent statistically significant findings at p<0.05.
CLBP, chronic lower back pain; HRQoL, health-related quality of life; SF-6D, Short Form-6 dimensions; SF-36, short form-36.